Anzeige
Meldung des Tages: Breaking News: TeaRx™ erobert Großbritannien im Sturm?!

Savara Aktie News

Aktie
WKN:  A2DQ2B ISIN:  US8051111016 US-Symbol:  SVRA Branche:  Biotechnologie Land:  USA
4,70 €
+0,00 €
0,00%
11:24:55 Uhr
Depot/Watchlist
Marktkapitalisierung *
1,11 Mrd. €
Streubesitz
11,72%
KGV
-6,40
Index-Zuordnung
-

Savara News

20.02.26 - Businesswire
Savara Announces the U.S. Food and Drug Administration (FDA) Filed the MOLBREEVI* Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical-​stage biopharmaceutical company focused on rare respiratory diseases, announced the FDA has filed for review the BLA for ...
13.02.26 - Businesswire
Savara Announces New Employment Inducement Grant
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to a new employee.
04.02.26 - Businesswire
Savara Announces Participation in Upcoming Investor Healthcare Conferences
Savara Inc. (Nasdaq: SVRA ) (the “Company”), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of its management ...
27.01.26 - Businesswire
Savara Announces Amendment to Hercules Capital Debt Facility Providing up to $75M of Additional Debt Funding Upon U.S. Food and Drug Administration (FDA) Approval of MOLBREEVI*
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the amendment of its loan and ...
16.01.26 - Businesswire
Savara Announces New Employment Inducement Grant
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to two new ...
08.01.26 - Businesswire
PANTHERx® Rare Selected by Savara as the U.S. Exclusive Specialty Pharmacy for MOLBREEVI*
PANTHERx® Rare Pharmacy, the trusted leader and innovator in patient access and support services for personalized rare disease care, and Savara Inc. (Nasdaq: SVRA), a clinical ...
22.12.25 - Businesswire
Savara Resubmits the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
Savara Inc. (Nasdaq: SVRA ) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced today that it has resubmitted the ...
17.12.25 - Businesswire
Savara Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference
Savara Inc. (Nasdaq: SVRA ) (the “Company”), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of the management ...
11.12.25 - Businesswire
Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI*
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the EPO notified the Company of its ...
02.12.25 - Businesswire
Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Delivered Via the Proprietary eFlow® Nebulizer System
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the European Patent Office (EPO) has ...
07.11.25 - PR Newswire
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Savara Inc.(SVRA) Shareholders
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Savara Inc.(SVRA) Shareholders PR Newswire
07.11.25 - PR Newswire
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara PR Newswire
07.11.25 - PR Newswire
Savara Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SVRA
Savara Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SVRA PR Newswire
07.11.25 - PR Newswire
SVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit with the Schall Law Firm
SVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit with the Schall Law Firm PR Newswire
06.11.25 - PR Newswire
Shareholders of Savara Inc. Should Contact The Gross Law Firm Before November 7, 2025 to Discuss Your Rights - SVRA
Shareholders of Savara Inc. Should Contact The Gross Law Firm Before November 7, 2025 to Discuss Your Rights - SVRA PR Newswire
04.11.25 - PR Newswire
Savara Inc. (SVRA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Savara Inc. (SVRA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit PR Newswire
04.11.25 - PR Newswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of November 7, 2025 in Savara Inc. Lawsuit - SVRA
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of November 7, 2025 in Savara Inc. Lawsuit - SVRA PR Newswire
03.11.25 - PR Newswire
Shareholders that lost money on Savara Inc.(SVRA) should contact The Gross Law Firm about pending Class Action - SVRA
Shareholders that lost money on Savara Inc.(SVRA) should contact The Gross Law Firm about pending Class Action - SVRA PR Newswire
03.11.25 - PR Newswire
Savara Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SVRA
Savara Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SVRA PR Newswire
03.11.25 - PR Newswire
SVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit with the Schall Law Firm
SVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit with the Schall Law Firm PR Newswire

Newssuche

Videos

newspaper
18.02.26 -2,76%
Technical Trading: Chance mit 82 Prozent Treffern
Rohöl Long Typ: Turbo Open End WKN: VH65XQ Hebel:6 Laufzeit: OpenEnd Einstieg: Market ... Mehr »
Anzeige

Aktie im Fokus

Breaking News
DiagnosTear Technologies Inc
0,268 €
+5,51%
DiagnosTear Technologies Inc Chart
TeaRx™ erobert Großbritannien im Sturm?!
Mehr zur Aktie »